☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC December Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Liraglutide (Victoza®) has been accepted for restricted use for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control. It is restricted to a third line position after metformin and a sulphonylurea.

Pramipexole (Mirapexin®) in a modified release formulation has been accepted for use in the treatment of Parkinson’s disease. An economic analysis found that the once daily formulation could provide the benefit of once-daily rather than thrice-daily dosing, at an equivalent cost.

Tafluprost preservative-free eye drops (Saflutan®) have been accepted for restricted for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. The product is restricted to use in those patients with a proven sensitivity to the preservative benzalkonium chloride in currently available prostaglandin preparations.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC December Update' by emailShare 'SMC December Update' on FacebookShare 'SMC December Update' on TwitterShare 'SMC December Update' on LinkedInShare 'SMC December Update' on reddit


No Comments to “SMC December Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.